Aminophylline should not be considered an archaic agent, as it retains potential benefit as adjunctive therapy in specific cardiac conditions such as AV block, cardiac arrest, heart failure, and bradyarrhythmias.
Answers are grounded in this paper and cite their sources.
May support adjunctive aminophylline in refractory bradyarrhythmias or HF; leaves open need for randomized confirmation before practice change.
Although aminophylline/theophylline has been relegated to third- and fourth-line status in the cardiopulmonary armamentarium, its use in specific pathophysiologic states, especially those of cardiac etiology, can be of significant benefit. The consulting clinician should maintain an awareness of its potential as adjunctive therapy in cases of atrioventricular block, cardiac arrest, heart failure, and bradyarrhythmias in particular. It should not yet be shelved as an archaic agent.
No takes yet. Share an insight, caveat, or question.
Basil M. RuDusky (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: